Diagnostic Center | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
